Danaher Corporation $DHR Shares Bought by Catawba River Capital

Key Points

• Catawba River Capital increased its stake in Danaher Corporation by 37.6% during the second quarter, owning a total of 39,516 shares valued at approximately $7.8 million.
• Danaher's stock has a consensus target price of $244.60, with 17 analysts rating it as a Buy, while recent updates from major banks have set target prices ranging from $220.00 to $275.00.
• Danaher announced a quarterly dividend of $0.32 per share, with an ex-dividend date of September 26, reflecting a 0.6% yield and a payout ratio of 27.23%.

Catawba River Capital boosted its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 37.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,516 shares of the conglomerate's stock after buying an additional 10,805 shares during the period. Danaher accounts for approximately 4.0% of Catawba River Capital's portfolio, making the stock its 13th biggest holding. Catawba River Capital's holdings in Danaher were worth $7,806,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. increased its position in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after buying an additional 99 shares during the period. Sierra Ocean LLC increased its position in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after buying an additional 76 shares during the period. Red Tortoise LLC increased its position in Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate's stock worth $30,000 after buying an additional 98 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in Danaher during the first quarter worth approximately $31,000. Finally, Dunhill Financial LLC increased its position in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after buying an additional 67 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Guggenheim reiterated a "buy" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 target price on Danaher in a research note on Tuesday, September 2nd. Bank of America lowered their target price on Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research note on Monday, September 22nd. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Danaher in a research note on Wednesday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Danaher currently has an average rating of "Moderate Buy" and a consensus target price of $244.60.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 11.10% of the company's stock.

Danaher Stock Up 2.3%

Danaher stock opened at $210.86 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.41. The company has a market cap of $150.99 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.77. The stock's 50 day moving average price is $201.43 and its 200 day moving average price is $197.23.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the business earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher's payout ratio is currently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.